CClinicalTrials.gg
Sign In
Not yet recruitingNCT06006663Updated Aug 23, 2023

Effect of Hebal and Synthetic Medicamentss on Enterococcus Feacalis

A Phase 2/3 interventional study of Ibuprofen 400 mg. and modified triple antibiotic paste in Effective Intracanal Medicaments Against Enterococcus Faecalis, sponsored by Tanta University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2023-08-23.

Sponsored by Tanta University · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years ago, but the record still lists the study as not yet recruiting.
Phase
Phase 2/3
Study type
Interventional
Enrollment
32
Allocation
Randomized
Sex
All
01

Study summary

this study aims to evaluate the antimicrobial efficacy of two synthetic (Ibuprofen, Modified triple antibiotic paste) and two herbal materials (Curcumin and Olive leaves extract) used as intracanal medication, against E.Faecalis in secondary endodontic infection cases.

Read the detailed description

we evaluate the antimicrobial efficacy of two synthetic (Ibuprofen, Modified triple antibiotic paste) and two herbal materials (Curcumin and Olive leaves extract) used as intracanal medication, against E.Faecalis in secondary endodontic infection cases by taking three samples from root canal , the first sample after removing gutta percha from root canal system, the second sample after shaping with protaper universal files and cleaning with 2.5% sodium hypochlorite , the third sample after 7 days from application of the medication .

samples will be diluted into ten fold serial dilution and then the diluted samples will be cultured on bile esculin agar as it is selective media for enterococcus feacalis.

bacterial reduction will be determined and comparision will be made .

02

Conditions studied

  • Effective Intracanal Medicaments Against Enterococcus Faecalis
03

In context

Lead sponsor

Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Single rooted teeth.
  • Teeth have clinical signs and symptoms of endodontic failure as sensitivity to percussion, pain, swelling or fistula.
  • Teeth with radiographic features of endodontic failure as persistent periapical lesion or widening of periodontal ligament.

Exclusion criteria

Exclusion Criteria:

    • Teeth with fractures of the crown or root.

      • Teeth with periodontal pocket deeper than 4mm.
      • Teeth have procedural error like ledge, broken instrument, or perforation.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
32 participants (estimated)

Study arms

  • Active comparator
    group 1

    ibuprofen as intracanal medicament

    Drug: Ibuprofen 400 mg.

  • Active comparator
    group 2

    modified triple antibiotic paste as intracanal medicament

    Drug: modified triple antibiotic paste

  • Active comparator
    group 3

    curcumin as intracanal medicament

    Dietary Supplement: curcumin

  • Active comparator
    group 4

    olive leaves as intracanal medicament

    Dietary Supplement: olive leaves extract

Interventions

  • DrugIbuprofen 400 mg.

    synthetic intracanal medicament

  • Drugmodified triple antibiotic paste

    synthetic intracanal medicament

    Also known as: clindamycin, ciprofloxacin and metronidazole

  • Dietary supplementcurcumin

    herbal intracanal medicament

  • Dietary supplementolive leaves extract

    herbal intracanal medicament

06

What researchers measure

Primary outcomes

  1. measurment of microbial reduction as result of applying synthetic and herbaal intracanal medicaments

    sample 1 will be taken after gutta percha removal sample 2 will be taken after cleaning and shaping sample 3 will be taken after apllying the intracanal medicament for one week

    Time frame: time necessary for incubation of each sample is 24 hour

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06006663
Lead sponsor
Tanta University
Responsible party
Alaa Essam Ahmed Abo Laimon (Demonstrator , Endodontic department,Faculty of dentistry,Tanta university, Tanta University) — Principal investigator
First posted
Aug 23, 2023
Start date
Aug 26, 2023 (estimated)
Primary completion
Oct 5, 2023 (estimated)
Completion
Dec 10, 2023 (estimated)
Last update
Aug 23, 2023

Study contacts

alaa essam abo laimon, demonstrator at university
Contact
alaalamona@yahoo.com
01005690958

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Tanta University

Start the discussion